Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in Patients With R/R B-Cell Acute Lymphoblastic Leukemia
Conditions
Interventions
Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
Cyclophosphamide,Fludarabine
Locations
1
China
Hebei Yanda Ludaopei Hospital
Langfang, Hebei, China
Start Date
August 15, 2021
Primary Completion Date
August 1, 2023
Completion Date
November 1, 2023
Last Updated
February 7, 2022
Lead Sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions